OccuLogix, Inc. (NASDAQ: RHEO)(TSX: RHE) today announced that it has signed a definitive merger agreement to acquire SOLX, Inc. (“SOLX”) pursuant to the Company’s previously announced diversification plans focusing on age-related eye diseases. Based at the world renowned Boston University Photonics Center in Boston, Massachusetts, SOLX is a privately held company developing novel approaches to the treatment of glaucoma.
